DexCom, Inc. $DXCM Position Lowered by Perfromance Wealth Partners LLC

Perfromance Wealth Partners LLC decreased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 18.2% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 28,626 shares of the medical device company’s stock after selling 6,370 shares during the period. Perfromance Wealth Partners LLC’s holdings in DexCom were worth $2,499,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Golden State Wealth Management LLC lifted its holdings in DexCom by 211.2% in the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock worth $27,000 after acquiring an additional 264 shares during the last quarter. Zions Bancorporation National Association UT bought a new position in DexCom in the first quarter worth about $27,000. Anderson Financial Strategies LLC bought a new position in DexCom in the first quarter worth about $37,000. Alpine Bank Wealth Management bought a new position in DexCom in the first quarter worth about $40,000. Finally, Private Trust Co. NA lifted its holdings in DexCom by 99.4% in the first quarter. Private Trust Co. NA now owns 672 shares of the medical device company’s stock worth $46,000 after acquiring an additional 335 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $65.20 on Tuesday. The firm’s 50 day moving average is $74.20 and its two-hundred day moving average is $77.70. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $93.25. The firm has a market capitalization of $25.57 billion, a P/E ratio of 45.28, a PEG ratio of 1.37 and a beta of 1.47. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same quarter last year, the business earned $0.43 earnings per share. DexCom’s revenue was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. Analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Raymond James Financial raised their target price on shares of DexCom from $99.00 to $102.00 and gave the stock a “strong-buy” rating in a report on Thursday, July 31st. William Blair raised shares of DexCom to a “strong-buy” rating in a report on Thursday, July 31st. The Goldman Sachs Group cut their target price on shares of DexCom from $104.00 to $89.00 and set a “buy” rating on the stock in a report on Wednesday, October 1st. Argus started coverage on shares of DexCom in a report on Thursday, August 21st. They issued a “buy” rating and a $100.00 target price on the stock. Finally, Wall Street Zen lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, August 10th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and a consensus price target of $97.42.

Insider Activity at DexCom

In related news, Director Mark G. Foletta sold 2,750 shares of the firm’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $81.06, for a total transaction of $222,915.00. Following the transaction, the director owned 51,121 shares in the company, valued at $4,143,868.26. This trade represents a 5.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Sadie Stern sold 1,466 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $80.00, for a total transaction of $117,280.00. Following the transaction, the executive vice president owned 105,223 shares in the company, valued at $8,417,840. This represents a 1.37% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,849 shares of company stock worth $564,733 over the last ninety days. Insiders own 0.32% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.